Latest Conference Coverage

The senior investigator at the National Institutes of Neurological Disorders and Stroke outlined studies on anakinra and tolebrutinib as part of a new phase 2a clinical trial paradigm.

There was very good to excellent level of agreement between the instrumented insoles and the gold-standard reference system.

The Neuroimmunology Clinical Fellow at the National Institutes of Health discussed the evaluations of 2 therapies in multiple sclerosis that she is partaking in.

Two-year data from the SUNFISH study were presented at the MDA 2021 Clinical and Scientific Conference.

The postdoctoral researcher at Columbia University discussed ways clinicians and patients with multiple sclerosis can take to ease the transition of disclosing their diagnosis.

The AURORA collaboration studied pooled study data from 6 randomized studies of ET in ischemic stroke.

Researchers conducted a real-world study of prednisone to deflazacort switch in patients with Duchenne muscular dystrophy and Becker muscular dystrophy.

The neurologist from the University of Washington Medical Center discussed the findings of her recent study presented at ACTRIMS Forum 2021.

Black patients were 16% less likely and Asian patients were 30% less likely to be able to function independently compared to non-Hispanic white patients following endovascular treatment.

The findings were consistent with the established safety profile for eculizumab in other non-neurologic indications, according to study authors.

The president of the Americas Committee for Treatment and Research in MS shared his perspective on the impact of COVID and the top talks at the ACTRIMS Forum 2021.

The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed the potential of interleukin-1 receptor antagonist as a biomarker in MS disability as well as a therapeutic target.

NeurologyLive’s coverage of ACTRIMS Forum 2021 featured a number of insightful conversations with leading experts in multiple sclerosis care.

Over a 2-year period, SRP-9003 elicited sustained protein expression in muscle tissue and stabilized North Star Assessment for Dysferlinopathies scores.

Researchers used predictive swallowing score to help guide decision making in gastric tube placement.

Black patients accounted for 27% of the patients in the COVID-19 CVD Registry but accounted for 31% of the ischemic stroke cases.

Researchers also found that compared to direct to CT patients, DTAS patients has lower onset-to-reperfusion and door-to-groin times.

A greater proportion of patients identified by newborn screening achieved a greater than 4-point increase in CHOP-INTEND scores during the observation period compared to those clinically diagnosed.

The neurologist from Massachusetts General Hospital discussed when to prescribe disease-modifying therapy and some challenges in caring for patients with RIS.

Researchers found that physical activity as measured by wearable devices was significantly associated with in-person measures of strength and function in patients with CMT.

The findings suggest the externally altered proprioceptive feedback in forced exercises may be increasing cortical engagement.

Most treatment-emergent adverse events were mild in severity across both studies, with no evidence of renal toxicity, cardiac signals, or deaths.

Treatment with tPA within 0 to 60 minutes of last known normal occurred for 33% of patients on mobile stroke units, compared to 3% who received standard management.

The fellow of autoimmune neurology at Massachusetts General Hospital discussed the need for follow-up with patients long-term after TNFα inhibitor treatment.

Researchers conducted a pooled safety analysis of the FIREFISH, SUNFISH, and JEWELFISH studies.

Scholar Rock noted that the topline results from the 52-week treatment period are expected to be announced in the second quarter of 2021.

The postdoctoral researcher at Columbia University detailed a number of topics regarding the impact concealing multiple sclerosis diagnosis can have on a patient.

Ishu Arpan, PhD, senior research associate at Oregon Health & Science University, also discussed further studies she would like to see conducted in MS falls.